Here is the rundown on market activity for Nektar Therapeutics (NASDAQ:NKTR). John Nicholson, Sr VP disclosed the sale of 101,700 shares of NKTR stock. The shares were sold on June 7th for an average price of $19.24. Nicholson now owns $4,372,155 of the stock per the Form 4 SEC filing. Gil M. Labrucherie, Sr VP reported the sale of 3,179 shares. The shares were purchased at an average price of $19.55. The Sr VP now owns $1,292,079 of the stock according to the SEC filing.
President & CEO Howard W. Robin disclosed the sale of 8,388 shares of (NKTR). The shares were purchased at an average price of $19.55. The President & CEO now owns $3,145,282 of the stock per the Form 4 SEC filing.
Nektar Therapeutics, launched on June 3, 1998, is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Business’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates. These drug candidates utilize its polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Its programs include Immuno-oncology (I-O), Immunology, Pain-NKTR-181 and Oncology-ONZEALD..
These funds have also shifted positions in (NKTR). As of quarter end Tower Research Capital LLC (trc) had disposed of 904 shares trimming its holdings by 90.0%. The value of the investment in Nektar Therapeutics decreased from $12,000 to $2,000 a change of $10,000 quarter over quarter. As of the end of the quarter Goldman Sachs Group Inc had bought a total of 21,738 shares growing its position 29.2%. The value of the total investment in Nektar Therapeutics went from $914,000 to $2,259,000 a change of 147.2% for the reporting period.
Janus Capital Management LLC divested its stake by selling 78,623 shares a decrease of 4.4% as of 03/31/2017. Janus Capital Management LLC now holds 1,709,729 shares worth $40,125,000. The total value of its holdings increased 82.8%. As of the end of the quarter Hightower Advisors, LLC had bought a total of 16,225 shares growing its stake by 3,245.0%. The value of the investment in (NKTR) increased from $1,000 to $391,000 increasing 39,000.0% since the last quarter.
On November 8 analysts at Aegis Capital started covering NKTR setting a rating of “Buy”. On January 28, 2016 Janney Capital initiated coverage on NKTR giving it an initial rating of “Buy”.
On March 18 JP Morgan maintained a stock rating of “Overweight” but lowered the price target to $17.00 from $19.00. March 18 investment analysts at Jefferies held the company rating at “Buy” and lowered the price expectation from $17.00 to $14.00.
September 17 investment analysts at Bank of America made no change to the company rating of “Underperform” but moved up the price target to $11.00 from $10.00. September 16 investment analysts at Brean Capital left the stock rating at “Buy” and moved up the price target to $20.00 from $18.00.
In the market the company is trading up from yesterday’s close of $18.655. Shares last traded at $19.02 which is just under $19.27, the stock’s 50 day moving average and just above the 200 day moving average of $16.02. The 50 day moving average went down by -1.28% and the 200 day average moved up $3.00.
As of the latest earnings report the EPS was $-1.37 and is projected to be $-1.19 for the current year with 155,149,000 shares now outstanding. Analysts expect next quarter’s EPS to be $-0.21 and the next full year EPS is anticipated to be $-1.01.
Traders are more bullish on the company recently if you take note of the motion in short interest. The company experienced a fall in short interest of -5.54% as of the latest report on April 28, 2017. Short shares fell 551,995 over that timeframe. The short-interest ratio increased to 6.5 and the percentage of shorted shares is 0.06% as of April 28.